Answers are grounded in this paper and cite their sources.
Objective To construct and validate a contrast-enhanced ultrasound (CEUS) radiomics-clinical model for predicting transarterial chemoembolization (TACE) resistance in hepatocellular carcinoma (HCC). Methods A total of 168 HCC patients who underwent CEUS on two vendor platforms (Philips E9 and GE Logiq E95) were split into a training set (n = 118) and an internal validation set (n = 50), with an additional 80 patients forming an external validation cohort. For each patient, 2D regions of interest were manually delineated on the largest cross-sectional slice of each CEUS phase. Radiomic features were extracted and screened by LASSO regression; the twelve retained features were linearly combined into a single Rad-score. The Rad-score and three prespecified clinical risk factors (tumor size, Child-Pugh class, AFP) confirmed by multivariate analysis were combined into a parsimonious logistic regression (LR) model with four predictors in total. Performance was assessed by ROC curve, calibration curve, decision curve analysis (DCA), subgroup analysis, and prospective validation. Results The combined model had AUCs of 0.895, 0.891 and 0.846 in three sets, with subgroup AUCs >0.86. Prospective validation showed TACE plus sorafenib improved 6-month response rate from 26.7% to 53.3% for high-risk patients. Conclusion The CEUS radiomics-clinical model accurately predicts TACE resistance, guiding individualized HCC treatment. Advances in Knowledge This model integrates CEUS multi-phase radiomics and clinical factors, outperforming single clinical/radiomic models. Strict multi-step screening and comprehensive validation avoid data leakage, ensuring robust prediction and clinical translatability.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: